Prevalence, Clinical Characteristics, Progression, and Management of Neurofibromatosis Type 1 in Egypt (NF1-Egy)

Plain-language summary

This observational study looks at the prevalence, clinical characteristics, progression and management of neurofibromatosis type 1 (NF1) in Egypt. People of any age diagnosed with NF1 and/or plexiform neurofibroma according to NIH criteria may take part. The study does not use a clinical phase and is currently recruiting participants.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Recruiting

Sponsor

AstraZeneca

Start date

11/19/2025

Estimated completion

9/30/2026

Countries

Egypt

Related genes

Locations

• Al Mansurah, Egypt
• Alexandria, Egypt
• Aswān, Egypt
• Asyut, Egypt
• Cairo, Egypt
• Cairo, Egypt
• Sohag, Egypt
• Tanta, Egypt
• Zagazig, Egypt

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

A. Male or female patients of any age at index date (first diagnosis of NF1 and/or PN).

B. Have been diagnosed with NF1 according to the NIH Consensus Development Conference diagnostic criteria or the revised criteria between 01-Jan- 2010 and 31-December-2023.

Exclusion Criteria:

A. Missing NF1 diagnosis data in their medical record.